Melancholic features in major depression - a European multicenter study
| Autor: | Stuart Montgomery, Chiara Fabbri, Marleen M. M. Mitschek, Gernot Fugger, Daniel Souery, Joseph Zohar, Alessandro Serretti, Julien Mendlewicz, Siegfried Kasper, Alexander Kautzky, Lucie Bartova, Markus Dold |
|---|---|
| Přispěvatelé: | Dold M., Bartova L., Fugger G., Kautzky A., Mitschek M.M.M., Fabbri C., Montgomery S., Zohar J., Souery D., Mendlewicz J., Serretti A., Kasper S. |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Pregabalin Antidepressant Major depressive disorder Treatment response Logistic regression behavioral disciplines and activities 03 medical and health sciences Benzodiazepines 0302 clinical medicine Pharmacotherapy mental disorders Melancholia Outpatients medicine Prevalence Humans Augmentation/combination treatment Psychiatry Biological Psychiatry Depression (differential diagnoses) Pharmacology Clinical Trials as Topic Depressive Disorder Major Inpatients business.industry Middle Aged medicine.disease Antidepressive Agents 030227 psychiatry Europe Adjunctive treatment Female medicine.symptom business Selective Serotonin Reuptake Inhibitors medicine.drug Antipsychotic Agents |
| Zdroj: | Progress in neuro-psychopharmacologybiological psychiatry. 110 |
| ISSN: | 1878-4216 |
| Popis: | There is still a debate, if melancholic symptoms can be seen rather as a more severe subtype of major depressive disorder (MDD) or as a separate diagnostic entity. The present European multicenter study comprising altogether 1410 MDD in- and outpatients sought to investigate the influence of the presence of melancholic features in MDD patients. Analyses of covariance, chi-squared tests, and binary logistic regression analyses were accomplished to determine differences in socio-demographic and clinical variables between MDD patients with and without melancholia. We found a prevalence rate of 60.71% for melancholic features in MDD. Compared to non-melancholic MDD patients, they were characterized by a significantly higher likelihood for higher weight, unemployment, psychotic features, suicide risk, inpatient treatment, severe depressive symptoms, receiving add-on medication strategies in general, and adjunctive treatment with antidepressants, antipsychotics, benzodiazepine (BZD)/BZD-like drugs, low-potency antipsychotics, and pregabalin in particular. With regard to the antidepressant pharmacotherapy, we found a less frequent prescription of selective serotonin reuptake inhibitors (SSRIs) in melancholic MDD. No significant between-group differences were found for treatment response, non-response, and resistance. In summary, we explored primarily variables to be associated with melancholia which can be regarded as parameters for the presence of severe/difficult-to treat MDD conditions. Even if there is no evidence to realize any specific treatment strategy in melancholic MDD patients, their prescribed medication strategies were different from those for patients without melancholia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect